Combivent Respimat Spray, Metered
NDC Package 0597-0024-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Combivent Respimat (ipratropium bromide and albuterol) sprays is a medication used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This formulation utilizes a spray, metered delivery system. Marketed by Boehringer Ingelheim Pharmaceuticals, Inc., this product is identified by NDC 0597-0024 and is authorized under FDA application NDA021747.

Identification & Billing

NDC Package Code
0597-0024-02
Package Description
1 CARTRIDGE in 1 CARTON / 120 SPRAY, METERED in 1 CARTRIDGE
Product Code
0597-0024
11-Digit Billing Format
00597002402
Billing Unit
GM - Billing unit of "gram" is used when a product is measured by its weight.
RxNorm Crosswalk
  • RxCUI: 1190220 - albuterol/ipratropium bromide 20/100 MCG/INHAL Metered Dose Inhalation Spray, 120 Actuations
  • RxCUI: 1190220 - 120 ACTUAT albuterol 0.1 MG/ACTUAT / ipratropium bromide 0.02 MG/ACTUAT Inhalation Spray
  • RxCUI: 1190220 - albuterol 0.1 MG/ACTUAT / ipratropium bromide 0.02 MG/ACTUAT Metered Dose Inhalation Spray, 120 ACTUAT
  • RxCUI: 1190225 - Combivent 20/100 MCG/INHAL Metered Dose Inhalation Spray, 120 Actuations
  • RxCUI: 1190225 - 120 ACTUAT albuterol 0.1 MG/ACTUAT / ipratropium bromide 0.02 MG/ACTUAT Inhalation Spray [Combivent]

Clinical Specifications

Proprietary Name
Combivent Respimat
Non-Proprietary Name
Ipratropium Bromide And Albuterol
Substance Name
Albuterol Sulfate; Ipratropium Bromide
Dosage Form
Spray, Metered - A non-pressurized dosage form consisting of valves which allow the dispensing of a specified quantity of spray upon each activation.
Administration Route
Respiratory (inhalation) - Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
Active Ingredient(s)
Pharmacologic Class
Usage Information
This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Regulatory & Marketing

Labeler Name
Boehringer Ingelheim Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA021747
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-01-2012
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0597-0024-02 identifies a specific commercial package of 1 cartridge in 1 carton / 120 spray, metered in 1 cartridge of Combivent Respimat, a human prescription drug labeled by Boehringer Ingelheim Pharmaceuticals, Inc.. This spray, metered is formulated for respiratory (inhalation) use and contains albuterol sulfate; ipratropium bromide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Boehringer Ingelheim Pharmaceuticals, Inc. on July 01, 2012. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

How is this Boehringer Ingelheim Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00597002402. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0597-0024-02
11-Digit CMS (5-4-2)
00597-0024-02

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.